Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract

Neoplasia

Volumn 9, Issue 1, 2007, Pages 18-22

  Ji, Eun Uhm ^a   Ho, Yeong Lim ^a   Won, Seog Kim ^a   Han, Yong Choi ^a   Hyun, Moo Lee ^a   Park, Byeong Bae ^a   Park, Keunchil ^a   Won, Ki Kang ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Cisplatin; Paclitaxel; Salvage therapy; Transitional cell carcinoma; Urothelium

Indexed keywords

CISPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MEDICAL SOCIETY; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; URINARY TRACT CARCINOMA; VOMITING;

EID: 33846849283     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06661     Document Type: Article

References (25)

1. Vaughn DJ (2000). Paclitaxel and carboplatin in bladder cancer: recent developments. Eur J Cancer 36 (Suppl 2), 7-12.
2. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, and Boyle MG (1999). Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17, 3173-3181.
3. Bellmunt J, Albanell J, Paz-Ares L, Climent MA, Gonzalez-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Diaz-Rubio E, Cortes-Funes H, et al. (2002). Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95, 751-757.
4. Scher HI and Norton L (1992). Chemotherapy for urothelial tract malignancies: breaking the deadlock. Semin Surg Oncol 8, 316-341.
5. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, et al. (1989). Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64, 2448-2458.
6. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA, et al. (1992). A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10, 1066-1073.
7. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, et al. (2000). Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18, 3068-3077.
8. Otto T, Bex A, Krege S, Walz PH, and Rubben H (1997). Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): a clinical phase II study. Cancer 80, 465-470.
9. Roth BJ and Bajorin DF (1995). Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol 153, 894-900.
10. Dreicer R, Gustin DM, See WA, and Williams RD (1996). Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 156, 1606-1608.
11. Rosenberg JE, Carroll PR, and Small EJ (2005). Update on chemotherapy for advanced bladder cancer. J Urol 174, 14-20.
12. Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, Hudes GR, Schultz SM, and Loehrer PJ (1994). Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12, 2264-2270.
13. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, and Markowitz AB (2002). Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 20, 937-940.
14. Sternberg CN (2001). Second-line treatment of advanced transitional cell carcinoma of the urothelial tract. Curr Opin Urol 11, 523-529.
15. Pectasides D, Glotsos J, Bountouroglou N, Kouloubinis A, Mitakidis N, Karvounis N, Ziras N, and Athanassiou A (2002). Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol 13, 243-250.
16. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, and Kilbourn RG (1990). A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8, 1050-1055.
17. Pycha A, Grbovic M, Posch B, Schnack B, Haitel A, Heinz-Peer G, Zielinski CC, and Marberger M (1999). Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract. Urology 53, 510-515.
18. Culine S (2002). The present and future of combination chemotherapy in bladder cancer. Semin Oncol 29, 32-39.
19. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, and Arning M (2005). Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23, 4602-4608.
20. Kattan J, Culine S, Theodore C, and Droz JP (1995). Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer. Cancer Invest 13, 276-279.
21. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, and Bajorin DF (1997). Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15, 1853-1857.
22. Pagliaro LC, Millikan RE, Tu SM, Williams D, Daliani D, Papandreou CN, and Logothetis CJ (2002). Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol 20, 2965-2970.
23. Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, and Crawford ED (2005). Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma. Cancer 104, 1627-1632.
24. Bellmunt J, Ribas A, Eres N, Albanell J, Almanza C, Bermejo B, Sole LA, and Baselga J (1997). Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80, 1966-1972.
25. Petrioli R, Frediani B, Manganelli A, Barbanti G, De Capua B, De Lauretis A, Salvestrini F, Mondillo S, and Francini G (1996). Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 77, 344-351.